EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021

Amanda Azevedo Bittencourt iD, Vinicius Lima Faustino iD, Paula de Mendonça Batista, Lays Paulino Leonel, Marina Della Negra de Paula, Thales José Polis

Microbiology Spectrum · 2025-07 · 13 (7)

DOI: 10.1128/spectrum.02543-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025-07. Verfasst von Amanda Azevedo Bittencourt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, Brazil. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Imipenem, Azabicyclo Compounds, Enterobacteriaceae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of Enterobacterales (Klebsiella pneumoniae and Escherichia coli ) collected across six Brazilian cities during 2020–2021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Enterobacterales isolates were screened for β-lactamase genes ( bla ) by sequencing. The most frequent isolates identified among Enterobacterales were E. coli ( n = 471; 20.9%) and K. pneumoniae ( n = 453; 20.1%). Susceptibility testing showed that >99% of E. coli isolates were susceptible to colistin ([COL], n = 470; 99.8%), meropenem ([MEM], n = 468; 99.4%), IMR ( n = 468; 99.4%), and ceftazidime/avibactam ([CZA], n = 468; 99.4%), whereas a high proportion of E. coli multidrug-resistant (MDR) isolates were susceptible to COL ( n = 69; 98.6%), CZA ( n = 67; 95.7%), MEM ( n = 67; 95.7%), IMR ( n = 67; 95.7%), and amikacin ([AMK], n = 66; 94.3%). Overall, K. pneumoniae isolates were most susceptible to CZA ( n = 414; 91.4%) and IMR ( n = 411; 90.7%) and over 86.0% of K. pneumoniae MDR isolates were susceptible to CZA ( n = 268; 87.3%) and IMR ( n = 265; 86.3%). This study reported that IMR was one of the most effective in vitro β-lactam–β-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the Enterobacterales species tested. IMPORTANCE As new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsImipenemAzabicyclo CompoundsEnterobacteriaceaeBrazilHumansMicrobial Sensitivity TestsKlebsiella pneumoniaeEscherichia coliHospitalsbeta-LactamasesEnterobacteriaceae InfectionsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Enterobacteralesantibioticsbacterial infectionsimipenem/relebactamsurveillance

Substanzen

Anti-Bacterial AgentsImipenemAzabicyclo Compoundsrelebactambeta-Lactamases

Autor:innen und Institutionen

  • Global Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, Brazil.
  • Real World Evidence, IQVIA Brazil, São Paulo, Brazil.

ORCID-Profile: Amanda Azevedo Bittencourt, Vinicius Lima Faustino

Zitieren

APA

Bittencourt, A. A., Faustino, V. L., Batista, P. M., Leonel, L. P., Paula, M. D. N., & Polis, T. J. (2025). In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021. Microbiology Spectrum, 13(7). https://doi.org/10.1128/spectrum.02543-24

Vancouver

Bittencourt AA, Faustino VL, Batista PM, Leonel LP, Paula MDN, Polis TJ. In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021. Microbiology Spectrum. 2025;13(7). doi:10.1128/spectrum.02543-24

BibTeX
@article{Bittencourt2025,
  author = {Bittencourt, Amanda Azevedo and Faustino, Vinicius Lima and Batista, Paula de Mendonça and Leonel, Lays Paulino and Paula, Marina Della Negra de and Polis, Thales José},
  title = {In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {7},
  doi = {10.1128/spectrum.02543-24}
}
Kostenlos starten →